
|Podcasts|July 29, 2022
Pharmacy Focus: Psychedelic Pharmacy - Investigating Ketamine for Chronic Pain Management, Addiction Treatment
This month, we spoke with Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, about ketamine and the future of the opioid epidemic.
Advertisement
This month, we spoke with Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, about how investigative psychedelic treatments could help treat both chronic pain as well as addiction, and what this could mean for the future of the opioid epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Denosumab Biosimilars, Osvyrti and Jubereq, for Reference Products’ Indications
2
CDC’s Autism Statement Sparks New Concerns Over Vaccine Safety Messaging
3
Billions at Stake: 340B Program Integrity and Sustainability in 2024–2025
4
Patients With Long COVID Face Varying Trajectories, With Most Facing Symptoms Long After Infection
5












































































































































































































